0 NASDAQ Companies - July 23, 2024Climb Global Solutions Sets Second Quarter 2024 Conference Call for August 7, 2024 at 8:30 a.m. ETEATONTOWN, N.J., July 23, 2024 (GLOBE NEWSWIRE) — Climb Global Solutions, Inc. (NASDAQ:CLMB) (“Climb” or the “Company”), a value-added global […]Read More
0 NASDAQ Companies - July 23, 2024TIAN RUIXIANG Holdings Ltd Regains Compliance with Nasdaq’s Periodic Filing RequirementBEIJING, July 23, 2024 (GLOBE NEWSWIRE) — TIAN RUIXIANG Holdings Ltd (Nasdaq: TIRX) (the “Company”), a China-based insurance broker conducting […]Read More
0 NASDAQ Companies - July 23, 2024NANO Nuclear Energy Files Provisional Patents to Secure its Newly Acquired Annular Linear Induction Pump TechnologyThe Annular Linear Induction Pump (ALIP) is a key enabling technology for NANO Nuclear’s ‘ODIN’ microreactor in development and the […]Read More
0 NASDAQ Companies - July 23, 2024Hudson Technologies to Host Conference Call to Discuss Second Quarter 2024 ResultsWOODCLIFF LAKE, N.J., July 23, 2024 (GLOBE NEWSWIRE) — Hudson Technologies, Inc. (NASDAQ: HDSN) will host a conference call and […]Read More
0 NASDAQ Companies - July 23, 2024Adial Pharmaceuticals Advances to Second Cohort in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use DisorderGLEN ALLEN, Va., July 23, 2024 (GLOBE NEWSWIRE) — Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage […]Read More
0 NASDAQ Companies - July 23, 2024First Pediatric Patient Treated in a Commercial Setting with SeaStar Medical’s FDA-Approved QUELIMMUNE Therapeutic DeviceDENVER, July 23, 2024 (GLOBE NEWSWIRE) — SeaStar Medical Holding Corporation (Nasdaq: ICU) (SeaStar Medical) reports treatment of the first […]Read More
0 NASDAQ Companies - July 23, 2024Olaplex Holdings, Inc. to Report Second Quarter Fiscal 2024 Financial Results on August 6thNEW YORK, July 23, 2024 (GLOBE NEWSWIRE) — Olaplex Holdings, Inc. (“OLAPLEX”), today announced that it plans to report second […]Read More
0 NASDAQ Companies - July 23, 2024Cellectar Biosciences’ Iopofosine I 131 Exceeds Primary Endpoint in Waldenstrom’s Macroglobulinemia Pivotal Study with 78% of Major Response Patients Remaining Progression Free at 18 Months56.4% major response rate exceeded 20% primary endpoint 98.2% disease control rate achieved in heavily pretreated patients Responses shown in […]Read More
0 NASDAQ Companies - July 23, 2024H World Group Limited Announces Shareholder Return PlanSINGAPORE and SHANGHAI, China, July 23, 2024 (GLOBE NEWSWIRE) — H World Group Limited (NASDAQ: HTHT and HKEX: 1179) (“H […]Read More
0 NASDAQ Companies - July 23, 2024Grab to Announce Second Quarter 2024 Results on August 15, 2024NEW YORK, July 23, 2024 (GLOBE NEWSWIRE) — Grab Holdings Limited (NASDAQ: GRAB, the “Company” or “Grab”), plans to announce […]Read More